{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:53:20Z","timestamp":1792083200213,"version":"4.4.0"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Guidelines recommend that the therapeutic goal of urate\u2010lowering therapy (ULT) is to achieve a urate concentration of \u22646\u2003mg\u2003dl<jats:sup>\u22121<\/jats:sup>.<\/jats:p><jats:p>\u2022\u2003High\u2010dose allopurinol is associated with reduced cardiovascular events and mortality in heart failure patients.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Less than 50% of patients taking allopurinol reached target urate concentration.<\/jats:p><jats:p>\u2022\u2003Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality in all patients on allopurinol treatment.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> To characterize patients with urate measurements by urate\u2010lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> A cohort study using a record\u2010linkage database. The study included 7135 patients aged \u226560 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> Six thousand and forty\u2010two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations \u22646\u2003mg\u2003dl<jats:sup>\u22121<\/jats:sup>. Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non\u2010ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95\u20131.26] and the non\u2010ULT group with urate &gt;6\u2003mg\u2003dl<jats:sup>\u22121<\/jats:sup> (adjusted HR 1.07, 95% CI 0.89\u20131.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9\u201386.1) per 1000 person years for the 100\u2003mg group, 69.7 (49.6\u201389.8) for the 200\u2003mg group and 47.6 (38.4\u201356.9) for the \u2265300\u2003mg group. Compared with low\u2010dose (100\u2003mg) users, high\u2010dose (\u2265300\u2003mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50\u20130.94) and mortality (adjusted HR 0.75, 95% CI 0.59\u20130.94).<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Less than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03887.x","type":"journal-article","created":{"date-parts":[[2010,12,13]],"date-time":"2010-12-13T12:44:55Z","timestamp":1292244295000},"page":"600-607","source":"Crossref","is-referenced-by-count":82,"title":["Impact of allopurinol use on urate concentration and cardiovascular outcome"],"prefix":"10.1111","volume":"71","author":[{"given":"Li","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla S.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Struthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_7_3_2","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li\u2010Yu J","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.545"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091462"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0625"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000065637.10517.A0"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.18.2404"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24164"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.14.1546"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.3.746"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.87.3.229"},{"key":"e_1_2_7_14_2","first-page":"323","volume-title":"Pharmacoepidemiology","author":"Wei L","year":"2005"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy \u2013 I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02118.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.1.6"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.651117"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000084073"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00250-6"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60391-1"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.8.924"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep069"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055251"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"e_1_2_7_26_2","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.519793"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1333"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6908.846"},{"key":"e_1_2_7_30_2","unstructured":"Scottish health Survey.2003. Available athttp:\/\/www.scotland.gov.uk\/Resource\/Doc\/76169\/0019729.pdf. (last accessed on 5 January 2011)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03887.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03887.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:17:23Z","timestamp":1697429843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03887.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03887.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03887.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}